Loading
Why review: Watch for §301 review scope, exclusions, retaliation, or comment-window signals.
USTR has opened a Section 301 investigation into Germany's pharmaceutical pricing practices, alleging those practices are unreasonable or discriminatory and burden U.S. commerce. Importers and exporters with U.S.-Germany pharmaceutical supply chains should monitor this proceeding, as a Section 301 action can lead to tariff measures.
The investigation targets Germany specifically, and is focused on innovative pharmaceutical products. No HS headings or specific product categories beyond that description are named in the hearing or linked signal.
Official actions this hearing connects to across the primary sources Traverse tracks.